# An Investigational Immuno-therapy Study to Evaluate Safety and Effectiveness in Patients With Melanoma That Has Spread to the Brain, Treated With Nivolumab in Combination With Ipilimumab, Followed by Nivolumab by Itself

> **NCT02320058** · PHASE2 · COMPLETED · sponsor: **Bristol-Myers Squibb** · enrollment: 119 (actual)

## Conditions studied

- Melanoma

## Interventions

- **DRUG:** Ipilimumab
- **DRUG:** Nivolumab

## Key facts

- **NCT ID:** NCT02320058
- **Lead sponsor:** Bristol-Myers Squibb
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-03-05
- **Primary completion:** 2020-09-08
- **Final completion:** 2020-09-08
- **Target enrollment:** 119 (ACTUAL)
- **Last updated:** 2021-10-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02320058

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02320058, "An Investigational Immuno-therapy Study to Evaluate Safety and Effectiveness in Patients With Melanoma That Has Spread to the Brain, Treated With Nivolumab in Combination With Ipilimumab, Followed by Nivolumab by Itself". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT02320058. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*